Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression

M. Skerenova, V. Mikulova, O. Capoun, T. Zima, P. Tesarova

. 2017 ; 161 (3) : 272-280. [pub] 20170516

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18025565

BACKGROUND AND AIMS: Metastases are a severe complication in cancer patients and biomarkers predicting their progression are still lacking for specific groups of patients. HER2 positive breast cancer (HER2 BC) patients on trastuzumab therapy are at risk of the development of unpredictable and often fatal central nervous system (CNS) metastases and castration resistant prostate cancer (CRPC) patients urgently need a marker of disease progression during therapy. Proposed metastatic markers: circulating tumor cells (CTC), serum levels of matrix metalloproteinase 2 (MMP-2), 9 (MMP-9) and vascular endothelial growth factor (VEGF) were prospectively studied to confirm their utility in these two narrowly defined groups of cancer patients. PATIENTS AND METHODS: The groups comprised 44 advanced HER2 BC, 24 CRPC patients and 42 healthy controls. An immunomagnetic separation method followed by PCR and electrophoretic detection (AdnaGen, Germany) were used for CTC determination. Serum marker levels were determined by the ELISAs (R&D System, USA). RESULTS: MMP-2 serum level was significantly higher in HER2 BC patients who developed CNS metastases, especially if there were also bone metastases. CTCs were a negative predictive marker for overall survival in HER2 BC patients. MMP-9 serum level was significantly higher in CRPC patients in whom disease progression occurred. CTC vanished from the blood of most of the CRPC patients (from 88% to 37%) during chemotherapy. CONCLUSION: MMP-2 serum level and CTCs show the potential to predict CNS metastases and overall survival in BC patients. CTCs and MMP-9 serum level could be a promising therapy response marker in CRPC patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025565
003      
CZ-PrNML
005      
20180810085206.0
007      
ta
008      
180711s2017 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2017.022 $2 doi
035    __
$a (PubMed)28529342
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Škereňová, Markéta $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0208973
245    10
$a Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression / $c M. Skerenova, V. Mikulova, O. Capoun, T. Zima, P. Tesarova
520    9_
$a BACKGROUND AND AIMS: Metastases are a severe complication in cancer patients and biomarkers predicting their progression are still lacking for specific groups of patients. HER2 positive breast cancer (HER2 BC) patients on trastuzumab therapy are at risk of the development of unpredictable and often fatal central nervous system (CNS) metastases and castration resistant prostate cancer (CRPC) patients urgently need a marker of disease progression during therapy. Proposed metastatic markers: circulating tumor cells (CTC), serum levels of matrix metalloproteinase 2 (MMP-2), 9 (MMP-9) and vascular endothelial growth factor (VEGF) were prospectively studied to confirm their utility in these two narrowly defined groups of cancer patients. PATIENTS AND METHODS: The groups comprised 44 advanced HER2 BC, 24 CRPC patients and 42 healthy controls. An immunomagnetic separation method followed by PCR and electrophoretic detection (AdnaGen, Germany) were used for CTC determination. Serum marker levels were determined by the ELISAs (R&D System, USA). RESULTS: MMP-2 serum level was significantly higher in HER2 BC patients who developed CNS metastases, especially if there were also bone metastases. CTCs were a negative predictive marker for overall survival in HER2 BC patients. MMP-9 serum level was significantly higher in CRPC patients in whom disease progression occurred. CTC vanished from the blood of most of the CRPC patients (from 88% to 37%) during chemotherapy. CONCLUSION: MMP-2 serum level and CTCs show the potential to predict CNS metastases and overall survival in BC patients. CTCs and MMP-9 serum level could be a promising therapy response marker in CRPC patients.
650    _2
$a dospělí $7 D000328
650    _2
$a protinádorové látky imunologicky aktivní $x aplikace a dávkování $7 D000074322
650    _2
$a nádorové biomarkery $x krev $7 D014408
650    _2
$a nádory prsu $x krev $x metabolismus $x patologie $7 D001943
650    _2
$a nádory centrálního nervového systému $x krev $x sekundární $7 D016543
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a geny erbB-2 $7 D018734
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a matrixová metaloproteinasa 2 $x krev $7 D020778
650    _2
$a matrixová metaloproteinasa 9 $x krev $7 D020780
650    _2
$a lidé středního věku $7 D008875
650    12
$a metastázy nádorů $x patologie $7 D009362
650    _2
$a nádorové cirkulující buňky $x patologie $7 D009360
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a nádory prostaty rezistentní na kastraci $x krev $x patologie $7 D064129
650    _2
$a míra přežití $7 D015996
650    _2
$a trastuzumab $x aplikace a dávkování $x terapeutické užití $7 D000068878
650    _2
$a vaskulární endoteliální růstový faktor A $x krev $7 D042461
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mikulová, Veronika $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0208972
700    1_
$a Čapoun, Otakar, $u Department of Urology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic $d 1981- $7 xx0131076
700    1_
$a Zima, Tomáš, $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic $d 1966- $7 jn20000620440
700    1_
$a Tesařová, Petra, $u Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic $d 1961- $7 xx0102804
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 161, č. 3 (2017), s. 272-280
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28529342 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20180711 $b ABA008
991    __
$a 20180723100450 $b ABA008
999    __
$a ok $b bmc $g 1324899 $s 1022487
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 161 $c 3 $d 272-280 $e 20170516 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20180711

Najít záznam

Citační ukazatele

Možnosti archivace